|
Endocrinology Network Covers Incretin Based Treatments for Hyperglycemia
NORWALK, Conn., March 16, 2015 /PRNewswire/ -- UBM Medica US announces that Endocrinology Network, a leading online community for endocrinologists and other clinicians who treat patients with type 2 diabetes mellitus (T2DM) offers comprehensive and up-to-date coverage of incretin-based treatments for hyperglycemia.
The incretin system has become an important therapeutic target in the treatment of type 2 diabetes. Two classes of incretin-based drugs are available: the injectable glucagon-like peptide (GLP)-1 receptor agonists and oral dipeptidyl peptidase 4 (DPP-4) inhibitors. Both classes improve glycemic control and reduce body weight and also exhibit cardio-friendly properties. As post-marketing research continues, there is potential for additional class benefits to emerge.
Some highlights of incretin therapy coverage on Endocrinology Network include:
About UBM Medica US
Addressing today's healthcare information needs, UBM Medica US, delivers strategic, integrated communications solutions and comprehensive reach -- online, in print, via custom programs and live events. Improving the effectiveness of healthcare through information and education, UBM Medica US provides unbiased clinical, practical, and business information for physicians, providers and payers resulting in improved quality of care for patients around the world. Through journals, magazines, online communities, live and digital events, and other valuable resources, UBM Medica US also delivers comprehensive communication solutions for the pharmaceutical and related industries. Online communities include CancerNetwork.com, ConsultantLive.com, DiagnosticImaging.com, RheumatologyNetwork.com, OBGYN.net, PhysiciansPractice.com, PsychiatricTimes.com and SearchMedica.com. UBM Medica US is part of UBM Connect which, through a range of aligned interactive environments, both physical and digital – increases business effectiveness for both customers and audiences through meaningful experiences, knowledge and connections. Headquartered in New York, UBM Connect brings together UBM's healthcare business, UBM Medica US; UBM Canon's advanced design and manufacturing event, online and print brands; UBM Connect New York's catering, cruise shipping, customer management, and fine, specialty and custom chemical communities; and UBM Mexico's concrete show. For more information, visit www.UBMMedicaUS.com.
About UBM plc
UBM plc is a global events-led marketing services and communications company. We help businesses do business, bringing the world's buyers and sellers together at events and online, as well as producing and distributing news and specialist content. Our 5,500 staff in more than 30 countries are organized into expert teams which serve commercial and professional communities, helping them to do business and their markets to work effectively and efficiently.
For more information, go to www.ubm.com; follow us on Twitter at @UBM_plc to get the latest UBM corporate news.
Media contact:
Jason J. Golden
Content Marketing Manager
203-523-7040
Logo - http://photos.prnewswire.com/prnh/20150316/181980LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/endocrinology-network-covers-incretin-based-treatments-for-hyperglycemia-300050952.html
SOURCE UBM Medica US
[ Back To Homepage ]
|
Whitepaper 
